Meca Lallana, José E.Martínez Yélamos, SergioEichau, S.Llaneza, M. A.Martín Martínez, J.Peña Martínez, JoaquínMeca Lallana, VirginiaAlonso Torres, A.M.Moral Torres, E.Río, J.Calles, CarmenAres Luque, A.Ramió Torrentà, LluísMarzo Sola, M. E.Prieto, J. M.Martínez Ginés, María LuisaArroyo Pereiro, PabloOtano Martínez, M. Á.Brieva Ruiz, LuisGómez Gutiérrez, M.Rodríguez-Antigüedad Zarranz, A.Sánchez Seco, V. G.Costa Frossard, L.Hernández Pérez, M. Á.Landete Pascual, L.González Platas, M.Oreja Guevara, C.2024-07-152024-07-152024-03-011578-1968https://hdl.handle.net/2445/214564The last consensus statement of the Spanish Society of Neurology's Demyelinating Diseases Study Group on the treatment of multiple sclerosis (MS) was issued in 2016. Although many of the positions taken remain valid, there have been significant changes in the management and treatment of MS, both due to the approval of new drugs with different action mechanisms and due to the evolution of previously fixed concepts. This has enabled new approaches to specific situations such as pregnancy and vaccination, and the inclusion of new variables in clinical decision -making, such as the early use of high -efficacy disease -modifying therapies (DMT), consideration of the patient's perspective, and the use of such novel technologies as remote monitoring. In the light of these changes, this updated consensus statement, developed according to the Delphi method, seeks to reflect the new paradigm in the management of patients with MS, based on the available scientific evidence and the clinical expertise of the participants. The most significant recommendations are that immunomodulatory DMT be started in patients with radiologically isolated syndrome with persistent radiological activity, that patient perspectives be considered, and that the term lines of therapy no longer be used in the classification of DMTs (> 90% consensus). Following diagnosis of MS, the first DMT should be selected according to the presence/absence of factors of poor prognosis (whether epidemiological, clinical, radiological, or biomarkers) for the occurrence of new relapses or progression of disability; high-efficacy DMTs may be considered from disease onset. (c) 2023 Sociedad Espaniola de Neurologi ' a. Published by Elsevier Espania, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).13 p.application/pdfengcc by-nc-nd (c) Meca Lallana, José E. et al, 2024http://creativecommons.org/licenses/by-nc-nd/3.0/es/Esclerosi múltipleEspanyaMultiple sclerosisSpaininfo:eu-repo/semantics/article2024-06-17info:eu-repo/semantics/openAccess38237804